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Abstract
Background: Right ventricular structure and function is a major predictor of outcomes in pulmonary hypertension
(PH), yet the underlying mechanisms remain poorly understood. Growing evidence suggests the importance of
autophagy in cardiac remodeling; however, its dynamics in the process of right ventricle(RV) remodeling in PH has
not been fully explored. We sought to study the time course of cardiomyocyte autophagy in the RV in PH and
determine whether mammalian target of rapamycin (mTOR) and Beclin-1 hypoxia-related pro-autophagic pathways
are underlying mechanisms.
Methods: Rats were studied at 2, 4, and 6 weeks after subcutaneous injection of 60 mg/kg monocrotaline (MCT)
(MCT-2 W, 4 W, 6 W) or vehicle (CON-2 W, 4 W, 6 W). Cardiac hemodynamics and RV function were assessed in rats.
Autophagy structures and markers were assessed using transmission electron microscope, RT-qPCR,
immunohistochemistry staining, and western blot analyses. Western blot was also used to quantify the expression
of mTOR and Beclin-1 mediated pro-autophagy signalings in the RV.
Results: Two weeks after MCT injection, pulmonary artery systolic pressure increased and mild RV hypertrophy
without RV dilation was observed. RV enlargement presented at 4 weeks with moderately decreased function,
whereas typical characteristics of RV decompensation and failure occurred at 6 weeks thus demonstrating the
progression of RV remodeling in the MCT model. A higher LC3 (microtubule- associated protein light chain 3) II/I
ratio, upregulated LC3 mRNA and protein levels, as well as accumulation of autophagosomes in RV of MCT
rats indicated autophagy induction. Autophagy activation was coincident with increased pulmonary artery systolic
pressure. Pro-autophagy signaling pathways were activated in a RV remodeling stage-dependent manner since
phospho-AMPK (adenosine monophosphate-activated protein kinase)-α were primarily upregulated and phospho-
mTOR suppressed in the RV at 2 and 4 weeks post-MCT injection, whearas, BNIP3 (Bcl2-interacting protein 3) and
beclin-1 expression were relatively low during these stages, they were significantly upregulated after 6 weeks in this
model.
Conclusions: Our findings provide evidence of sustained activation of autophagy in RV remodeling of MCT induced
PH model, while pro-autophagic signaling pathways varied depending on the phase.
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Background
Pulmonary hypertension (PH) is a devastating and fatal
disease characterized by pulmonary vascular remodeling
and vasoconstriction, resulting in increased pulmonary
vascular resistance and subsequent right ventricular
(RV) hypertrophy and heart failure [1–3]. It has been
established that the RV function is the most important
prognostic factor for both morbidity and mortality of pa-
tients with PH [1–3]. Current interventions aimed at im-
proving RV function are suboptimal, [4, 5] which may be
partly due to the limited insights on the mechanisms
driving the progression of the RV from hypertrophy to
failure [2, 6, 7]. As a result, preserving RV function is
emerging as a critical research priority in the cardiopul-
monary research field [3].
Autophagy, a highly conserved lysosomal-dependent
process for the bulk degradation and recycling of long-
lived proteins and organelles, has recently emerged in
playing a pivotal role in cardiac remodeling [8].
Autophagy serves as a major mechanism for cellular
survival in cardiomyocytes [8, 9]. Paradoxically, excessive
autophagy may result in cardiomyocyte death and con-
tribute to cardiac dysfunction [8, 10, 11]. Microtubule
associated protein light chain 3 (LC3) is a crucial marker
of autophagy [10]. LC3 initially yields a cytosolic form
LC3-I, which is converted to LC3-II during the forma-
tion of autophagosomes. LC3-II is recruited to the
expanding autophagosomal membranes and associates
specifically with autophagosomes [12]. Thus, LC3 and
the ratio of LC3-II/LC3-I are considered markers of au-
tophagy. Autophagosomes can be observed using a
transmission electron microscope and are considered
“gold standards” in terms of morphological/ultrastruc-
tural evidence of autophagy activation, [13] while upreg-
ulation of p62 poses as a marker of autophagosomal
clearance [14, 15].
Presently, the disease-modifying effects of autophagy
in the progression of RV remodeling and the underlying
mechanisms remain poorly understood. Qipshidze et al.
were the first to demonstrate autophagy changes in the
RV of a pulmonary artery banding mouse model [16].
However, this model is associated with longer periods of
compensation, which clinically more closely mimics RV
remodeling in pulmonary stenosis [2]. A widely accepted
experimental model of PH is generated by injection of
monocrotaline (MCT), a pyrrolizidine alkaloid toxin that
selectively affects the pulmonary vasculature [17]. The
MCT induces PH, which mediates a gradual rise in pres-
sure load on the RV. This can induce compensatory RV
myocardial hypertrophy after the second week and cham-
ber expansion after 3–4 weeks, and result in marked RV
dilatation and global hypokinesis at 5–6 weeks [2, 7]. Thus,
the MCT model is characterized by RV failure similar to
humans, and is characterized by decreased activity,
ascites, overall weight loss, and increased mortality
[2, 3, 7]. Although the impact of autophagy has been
extensively studied in the pulmonary vasculature in the
MCT model, [18, 19] there is a paucity of data concerning
the impact of autophagy in the RV in the model [20].
The exact mechanisms underlying autophagic activa-
tion remain to be delineated precisely, however there is
emerging evidence for a critical role of autophagy signal-
ing in adaptive and maladaptive responses [21]. There
are two crucial pathways involved in the regulation of
autophagy during ischemia/hypoxia. One is the adeno-
sine monophosphate-activated protein kinase (AMPK)/
mammalian target of rapamycin (mTOR) and the other
is hypoxia inducible factor 1α (HIF-1α)/B-cell lymphoma
2 (Bcl2)/adenovirus E1B 19 kDa protein-interacting pro-
tein 3 (BNIP3)/Beclin-1 pathway [22, 23]. RV capillary
rarefaction, decreased coronary artery perfusion, reduc-
tion in RV myoglobin protein, and an enlargement of
RV cardiomyocytes leading to RV myocardial ischemia/
hypoxia are structural derangements contributing to the
progression of RV failure in PH [3, 24–27]. Thus, we
hypothesized that RV autophagy would be activated
through one or both of these signaling pathways. There-
fore, we aimed to establish the dynamics and potential
mechanisms of autophagy in the RV in vivo during RV
remodeling in the MCT rat model. These findings will
help to provide new mechanistic insights into pathways
that drive autophagy-mediated RV remodeling in PH.
Methods
Animal model
Animal protocols were approved by the Ethics Committee
of Animal Experiments at Guangxi Medical University and
conformed to the Guide for the Care and Use of Laboratory
Animals published by the National Institutes of Health.
Pathogen-free inbred male Sprague Dawley rats were
purchased from the Guangdong Laboratory Animal Center
at the Chinese Academy of Sciences (Certificate No. SCXK
[Yue] 2013–0002) and bred in a pathogen-free mouse room
at the Experimental Animal Center (Guangxi Medical
University, China). Rats were housed under controlled
temperatures (22 °C) in a humidity-controlled room using
a 12-h light:12-h dark cycle. All rats received standard rat
chow and water ad libitum. The rats (8-weeks-old, weight
250 to 280 g, n = 60) were randomly assigned to either the
MCT (n = 36) or control (n = 24) group. The MCT group
received a single 60 mg/kg subcutaneous injection of MCT
(Sigma-Aldrich, St. Louis, MO, USA), while the control
group received an equivalent volume of saline. Within each
group, rats were further subdivided according to injection
durations (2 weeks, 4 weeks, 6 weeks). These subgroups
were termed MCT-2 W (n = 12), MCT-4 W (n = 12), and
MCT-6 W (n = 12) as well as CON-2 W (n = 8), CON-4 W
(n = 8), and CON-6 W (n = 8).
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Transthoracic echocardiography
Echocardiography was performed at 2, 4, and 6 weeks.
The rats were anesthetized by intraperitoneal administra-
tion of 3% pentobarbital sodium (50 mg/kg) and subjected
to transthoracic echocardiography using a HP Sonos 7500
system (Philips Medical Systems, Andover, MA, USA)
equipped with a 12.0 MHz phase array transducer (S12-4
scanner). Echocardiography was performed according to
the recommendations of the American College of Echo-
cardiography [28]. RV wall thickness (RVWT), right
ventricular end-diastolic diameter (RVEDD), RV end-
systolic and end-diastolic areas (RVEDA, RVESA), as well
as Volumes (RVEDV, RVESV) were assessed in the apical
four-chamber view. RV fractional area change (RV FAC)
was calculated using the formula: RV FAC (%) = (RVEDA-
RVESA)/RVEDA× 100%. RV ejection fraction (RVEF) was
calculated using the formula: RVEF (%) = (RVEDV-
RVESV)/RVEDV× 100%. Tricuspid annular plane systolic
excursion (TAPSE) was obtained in M-mode as the
displacement of the lateral tricuspid annulus. Pulmonary
artery acceleration time (PAAT) assessed by pulse Doppler
was acquired as reported previously [29, 30]. All evalua-
tions were performed by an observer who was blinded to
the groups and each parameter was averaged over six
cardiac cycles.
Invasive right heart hemodynamic measurements
After echocardiography, the rats were anesthetized as
described above and placed in a supine position on a
heated pad. Using a closed chest model, an experienced
anesthesiologist isolated and cannulated the right exter-
nal jugular vein using a 2 F high fidelity microtip pres-
sure catheter under an Olympus CH30 microscope
(Olympus, Tokyo, Japan). The catheter was then inserted
into the superior vena cava (SVC), right atrium (RA), right
ventricle, and pulmonary artery as previously described
[31, 32]. Catheter position was determined in accordance
with changes in the pressure waveform. Pressure wave-
forms were low in the SVC and slightly increased in pulsa-
tility in the RA. When the catheter was inserted into the
RV, a waveform occurred as evidenced by a large step dur-
ing systole and a pressure drop to near zero during dia-
stole. Pulmonary artery systolic pressure (PASP) was
similar to the max RV pressure; however, the diastolic
pressure was elevated. Pulmonary artery waveforms were
recorded after a 10 min equilibration period with the
ALCB10 Heart Function Analysis System (Shanghai Al-
cott Biotech Co. Ltd, Shanghai, China). Data were aver-
aged from six consecutive cardiac cycles.
Histopathological analysis
After invasive hemodynamic analysis, RV, left ventricular
free wall (LV) and interventricular septal (IVS) tissues
were carefully separated, harvested, and weighed from
anesthetized rats. Right ventricular hypertrophy was
expressed as right ventricular weight (RV free wall) over
body weight (RV/BW) and left ventricular plus interven-
tricular septum weight [RV/(LV + IVS)] [2, 33, 34]. RV and
LV were flushed with physiological saline solution and
fixed with 10% formalin, and then embedded in paraffin.
Tissues were subjected to sectioning (5 μm thickness) as
well as hematoxylin and eosin (H&E) stain. Cardiac fibro-
sis was analyzed by staining RV tissue sections with Mas-
son’s trichrome stain, and collagen volume fraction (CVF)
was assessed as previously described [35]. Cardiomyocyte
cross-sectional area was assessed by staining RV tissues
with wheat germ agglutinin conjugated to Alexa Fluor®
488 dye (WGA, Invitrogen, Carlsbad, CA, USA) and
counterstained for nuclei with 4, 6-diamidino-2-phenylin-
dole (DAPI, Sigma-Aldrich, St. Louis, MO, USA). Images
were captured using an Olympus BP80 microscope and
software (Olympus, Tokyo, Japan). Using Image-Pro Plus
v6.0 software (Media Cybernetics, Rockville, MD, USA),
15 slices of RV tissue were evaluated for each animal.
Quantitative real time-polymerase chain reaction
The mRNA expression of autophagy marker LC3 was
quantified using real-time quantitative polymerase chain
reaction (RT-qPCR). Total RNA was isolated from rat
RV and LV free wall tissues using TRIzol (Invitrogen,
Carlsbad, CA, USA), and then subjected to reverse tran-
scription into cDNA using a Reverse Transcription Kit
(Takara, Dalian, China). The purity of RNA (260/280 nm
ratio) was determined spectrophotometrically using the
NanoDrop 2000 spectrophotometer (Thermo Fisher
Scientific Inc., Rockford, IL, USA). Two-step qRT-PCR
was used to quantify relative LC3 mRNA by the ABI
PRISM® 7500 qPCR System (Applied Biosystems, Foster
City, CA, USA) using SYBR Green. The relative LC3
mRNA expression was normalized to the level of
glyceraldehyde-3 phosphate dehydrogenase (GAPDH)
using ΔΔCT method. Each reaction was carried out in
triplicate. Using Primer Premier v5.0 software (PREM-
IER Biosoft International, Palo Alto, CA, USA), primers
for LC3 and GAPDH were designed as follows:









Deparaffinized myocardial tissue sections were subjected
to 3% hydrogen peroxide for 15 min. For heat-induced
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epitope retrieval, the sections were placed in a 0.01 mol/
L (pH 6.0) citrate buffer and heated at 120 °C for
10 min. Nonspecific binding was blocked by pre-
incubation with 5% goat serum in phosphate-buffered
saline for 20 min at room temperature. The sections
were incubated with a rabbit anti-LC3 antibody (diluted
1:3200, Cell Signaling, Danvers, MA, USA) in blocking
buffer for overnight at 4 °C. Phosphate-buffered saline was
used to wash sections. Sections and were then incubated
with streptavidin-biotin complex at room temperature for
20 min. Following extensive phosphate-buffered saline
washes, sections were subjected to 2% 3,3′-diaminobenzi-
dine in 50 mmol/L Tris buffer (pH 7.6) containing 0.3%
hydrogen peroxide for 5–10 min to develop the color
reaction. Sections were imaged (15 sections per rat) for
LC3 positivity with an Olympus BX51 microscope/soft-
ware (Olympus, Tokyo, Japan) and Image-Pro Plus v6.0
software (Media Cybernetics, Rockville, MD, USA). Two
pathology experts blindly scored and analyzed five random
fields from each section and plotted data using mean
integrated optical density (mean IOD) = IOD/area.
Transmission electron microscopy
RV tissue was dissected into 1 mm3 cubes and then
treated with 2% glutaraldehyde in phosphate-buffered sa-
line overnight at 4 °C, followed by post-fixation in 1%
buffered osmium tetroxide. Sections of RV tissue were
dehydrated in 70% acetone, and subjected to 1% phospho-
tungstic acid and 1% uranyl acetate solutions, followed by
further dehydration in acetone. RV tissue sections were
then embedded in resin and polymerized. Embedded
tissues were then subject to ultrathin sectioning (60–
70 nm) and contrast-staining with uranyl acetate and lead
citrate, followed by imaging using a transmission electron
microscopy (H-7650; Hitachi, Tokyo, Japan).
Western blot analysis
Myocardial tissues were homogenized in phosphate buf-
fer (150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 1 mM
EDTA, 1% Triton X-100, 1% sodium deoxycholate, and
0.1% SDS) with protease inhibitors and centrifuged at
12,000 rpm at 4 °C for 20 min to obtain supernatant.
Equal amounts of protein were separated by 10% SDS-
polyacrylamide gel and transferred onto nitrocellulose
membranes. Membrane were incubated at 4 °C over-
night with various primary antibodies, which included:
rabbit anti-LC3 monoclonal antibody (1:1000, Cell
Signaling Technology, Danvers, MA, USA); rabbit anti-
p62 polyclonal antibody (1:1000, Cell Signaling Tech-
nology, Danvers, MA, USA); rabbit anti-mTOR and
phospho-mTOR (Ser 2481) polyclonal antibodies
(1:1000, Cell Signaling Technology, Danvers, MA, USA);
rabbit anti-AMPKα and phospho-AMPKα (Thr172)
monoclonal antibodies (1:1000, Cell Signaling
Technology, Danvers, MA, USA); rabbit anti-p70S6 kin-
ase and phospho-p70S6 kinase (Ser424) monoclonal
antibodies (1:1000, Cell Signaling Technology, Danvers,
MA, USA); rabbit anti-Beclin-1 monoclonal antibody
(1:1000, Cell Signaling Technology, Danvers, MA, USA);
mouse anti-bcl-2 monoclonal antibody (1:1000, Santa
Cruz, CA, USA); rabbit anti-BNIP3 polyclonal antibody
(1:1000, Cell Signaling Technology, Danvers, MA, USA);
rabbit anti-HIF-1α polyclonal antibody (1:1000; Abcam,
Cambridge, UK); and rabbit anti β-actin polyclonal anti-
body (1:500, Santa Cruz, CA, USA). Membranes were
washed and subsequently incubated with HRP conju-
gated goat anti-rabbit secondary antibody (1:5000;
ZSGB-Bio, Beijing, China) for 1 h at room temperature.
Membranes were developed with enhanced chemilumin-
escence solutions, and protein bands were imaged using
a UVP gel imaging system (UVP, Upland, CA, USA).
Protein bands were digitized and subjected to densitom-
etry with Image J software (National Institutes of Health,
Bethesda, MD, USA). β-actin was used as a loading con-
trol to normalize the density of protein bands.
Statistical analysis
All data were expressed as mean ± standard deviation.
Data were statistically analyzed using Statistical Package
for the Social Sciences v17.0 software (SPSS Inc.,
Chicago, IL, USA). An unpaired t-test was used to com-
pare data between control and MCT rats at individual
time points. One-way ANOVA then q-test were used for
comparison of data from MCT rats at different time
points. Correlations were determined by Spearman’s
rank correlation coefficients. P < 0.05 was considered
statistically significant.
Results
General features of MCT model
Previous studies have established the natural history of
progression of RV hypertrophy to heart failure in the
MCT model [2, 7]. MCT rats enter a phase of decom-
pensation and heart failure in the fifth to sixth week
after MCT injection mimicking signs of human PH asso-
ciated with WHO class III and IV [2, 7]. Signs associated
with RV failure included decreased physical activity, asci-
tes, overall weight loss despite fluid retention (>20%),
and increased mortality [2]. To mimic the natural his-
tory of RV remodeling progression associated with MCT
in our study, we divided the animals into 2-, 4-, and 6-
week subgroups. MCT treatment over 2 (MCT-2 W), 4
(MCT-4 W), and 6 (MCT-6 W) weeks caused death in
0% (0/12), 16.7% (2/12), and 33.3% (4/12) rats, respect-
ively. In contrast, no rats died in the age-matched con-
trol subgroups during this induction period. In line with
previous studies, [2, 7] we demonstrated that rats sub-
jected to systemic MCT administration developed signs
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of PH (lethargy, respiratory distress, tachypnea) during
the second week and gradually worsened during the
fourth week. Subsequently, MCT rats presented typical
RV failure symptoms during the sixth week, as described
above. Of the 8 living rats in the MCT-6 W group, 6 of
8 presented with ascites and/or pleurisy, while all the
rats showed decreased appetite and activity as well as
obvious weight loss (Table 1). In clinical settings, mean
pulmonary arterial pressure (mPAP) ≥25 mmHg at rest
in patients, as assessed by right heart catheterization, is
considered PH [36]. While previous study showed that a
pulmonary artery systolic pressure (PASP) of 25 mmHg
is the cut-off value for PH in the MCT rat model [37].
Altogether, we had 12, 10, and 8 living MCT rats, in the
MCT-2 W, MCT-4 W, and MCT-6 W groups, respect-
ively, included in our study.
Hemodynamics and echocardiographic properties
To validate the PH and RV overload in our MCT model,
right heart catheterization was performed. The PASP in
MCT groups was significantly elevated compared to age-
matched controls (P < 0.05). Moreover, PASP progres-
sively increased with extended treatment times in MCT
rats (Table 1, Fig. 1). Pulmonary artery waveforms high-
light the presence of a dicrotic notch and a diastolic re-
coil phase after the dicrotic notch, which is widely
regarded as a sign showing the right heart catheter has
advanced into the pulmonary artery (Fig. 1) [30, 31]. The
high pulmonary arterial pressure in the MCT groups
was also reflected by the shorter pulmonary artery acceler-
ation time (Table 1, Fig. 2a-d) and the appearance of sys-
tolic notching in the Doppler flow waves, compared with
the normal-looking parabolic waves found in control rats.
To further verify whether MCT could recapitulate the
progressive RV remodeling in PH, echocardiography was
carried out to directly assess RV dimensions and systolic
function. It has been established that TASPE of <17.5 mm
in the MCT model, [38] RVEF of <40% [39] and RV FAC
of <35% [28] in clinical settings are widely used as gauges
for RV systolic dysfunction. TAPSE, RVEF, and RV FAC
were decreased, while RV end-diastolic dimension
(RVEDD) increased in MCT-4 W and MCT-6 W sub-
groups compared to the controls (Table 1, Fig. 2e-i).
TAPSE, RVEF, and RV FAC reached above cut-off values,
which was consistent with RV failure symptoms in the
MCT-6 W subgroup.
RV myocardial histology process
To corroborate the echocardiography findings, RV
tissues were assessed by quantitative histological ana-
lysis. Consistent with previous findings [2, 7], MCT-
treated rats showed a gradual increase in RV/BW and
RV/(LV + IVS) ratio from the second to sixth weeks
(Table 2). Similarly, RV cardiomyocyte cross-sectional
area progressively increased from the second to sixth
week after MCT treatment, as observed by WGA stain
(Fig. 3a-d, i). Myocardial fibrosis calculated by CVF was
also increased in RV tissues from MCT-4 W and MCT-
6 W subgroups compared to the MCT-2 W subgroup
and to a greater extent compared to age-matched con-
trols (Table 2, Fig. 3e-h, j).
Autophagy signature in the RV of MCT rats
The main objective of the study was to examine the time
course of changes in autophagy in the RV subsequent
MCT injection. Using RT-qPCR and immunochemistry,
we assessed the expression of the autophagosomal
marker LC3, which is a key protein involved in the
regulation of autophagy. We found that LC3 mRNA and
LC3 protein (as measured by densitometry) became













RVSP (mmHg) 23.3 ± 1.8 30.1 ± 1.5* 23.9 ± 1.6 37.1 ± 2.7**※ 24.7 ± 2.1 51.1 ± 3.7 **※※△
RVWT (mm) 0.911 ± 0.09 0.976 ± 0.15* 0.924 ± 0.11 1.18 ± 0.16**※ 0.932 ± 0.12 1.45 ± 0.13**※※△
RVEDD (mm) 36.3 ± 1.2 36.9 ± 1.1 37.9 ± 1.4 51.4 ± 2.9*※※ 38.7 ± 1.9 58.9 ± 2.7**※※△
BW (g) 355 ± 13 344 ± 16 398 ± 14 361 ± 21*※ 469 ± 17 357± 27**※※△
RVEDD/BW (mm/kg) 11.8 ± 0.8 10.7 ± 0.9 11.1 ± 0.7 14.1 ± 1.0*※ 10.9 ± 0.9 17.3 ± 1.3**※※△
HR (bpm) 375 ± 9 379 ± 8 383 ± 10 403 ± 8 374 ± 10 419 ± 13*
TAPSE (mm) 0.28 ± 0.013 0.29 ± 0.019 0.29 ± 0.014 0.24 ± 0.015*※ 0.30 ± 0.021 0.15 ± 0.026**※※△
RVEF (%) 61.5 ± 3.1 59.01 ± 2.1 63.8 ± 2.1 49.5 ± 3.6*※ 62.7 ± 2.9 35.5 ± 6.0**※※△
RV FAC (%) 55.1 ± 2.9% 54.1 ± 3.3% 54.1 ± 3.1% 43.5 ± 5.1%*※ 56.1 ± 2.7% 27 ± 3.9%**※※△
PAAT (ms) 32.2 ± 0.10 29.2 ± 0.15* 32.1 ± 0.11 25.9 ± 0.17**※ 31.4 ± 0.10 22.6 ± 0.19**※※△
RVSP Right ventricular systolic pressure, RVWT Right ventricular wall thickness, RVEDD Right ventricular diastolic diameter, BW Body weight, HR Heart rate (beats
per minute), TAPSE Tricuspid annular plane systolic excursion, RVEF Right ventricular ejection fraction, RV FAC Right ventricular fractional area change, PAAT
pulmonary artery acceleration time
Values are presented as mean ± standard deviation. *P < 0.05 and **P < 0.01, versus age-matched rat; ※P < 0.05, ※※P < 0.01, versus MCT-2 W; △P < 0.05, △△P < 0.01,
versus MCT-4 W
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markedly and gradually upregulated in the RV myocar-
dium during the progression of PH in MCT rats, and
reached its peak at sixth week after MCT treatment
(Fig. 4a-c). In contrast, both LC3 mRNA and LC3 pro-
tein remained low and constant in the controls at every
time point assessed after MCT treatment. Additionally,
no significant differences in these parameters could be
observed in the LV of MCT rats at these different time
points. Interestingly, LC3 levels in the MCT-treated
groups strongly correlated to pulmonary artery systolic
pressure (PASP), (r2 = 0.626, P < 0.01) (Fig. 4d).
Western blot analysis was further used to quantify
LC3-II/LC3-I ratio and p62 expression in rats. We
showed that the RV of MCT rats exhibited significantly
higher LC3-II/LC3-I ratios and p62 expression when
compared to age-matched controls, which reached peak
during the sixth week of MCT treatment (Fig. 5a and b).
Also, no significant difference in levels of these pro-
teins could be observed in the LV of MCT-treated
rats (Fig. 5c).
Transmission electron microscopy (TEM) was utilized to
verify that autophagosomes and morphological evidence of
autophagy activation were present in RV tissue of MCT-
treated animals. Characteristic ultrastructural features of
autophagosomes include a single or double membraned
structure that encompasses organelle remnants and cellular
cargo (arrow in Fig. 5d). Their presence gradually intensi-
fied during the RV disease progression in the MCT model.
Thus, autophagosomes were the most abundant within RV
cardiomyocytes of MCT-treated rats in the 6-week group.
In contrast, autophagosomes were rarely observed and
autolysosomes were never observed in controls Fig. 5d).
Distinct activation of pro-autophagic signaling pathways
Another objective of the study was to determine the
signaling pathways that may be involved in RV cardiac
autophagy in the MCT model, including mTOR (Ser
2481), AMPKα (Thr172), p70S6K (Ser424), Beclin-1
HIF-1α, Bcl2, and BNIP3. Using Western blot analysis,
we assessed the protein expression of each signaling
component in MCT-treated rats and controls at each
time point. Compared to controls, downregulation of
phosphorylated mTOR (normalized to total level) was
observed in RV of the MCT-2 W and MCT-4 W rats;
phosphorylated mTOR became upregulated in the RV of
the MCT-6 W group rats (Fig. 6a and b) This regulation
is likely achieved through a AMPK mechanism, as we
observed phosphorylated AMPKα (normalized to total
level) trended towards increased activation in the RV of
the MCT-2 W and MCT-4 W rats compared to controls;
however, it appears to decline in the RV of MCT-6 W
rats compared with the MCT-2 W and MCT-4 W
groups (Fig. 6a and c). Similarly, phosphorylated p70S6K
expression (normalized to total level), which is down-
stream of mTOR, paralleled the changes observed for
phosphorylated mTOR (Fig. 6a and d). No changes in
total mTOR, AMPKα, and p70S6K were observed in the
different groups (Fig. 6a and e–h).
In contrast, expression of BNIP3 and Beclin-1 was
relatively low in the RV of the MCT-2 W and MCT-4 W
groups, and then became significantly upregulated in the
MCT-6 W group compared with age-matched controls
(Fig. 7a–c). However, it appears that the BNIP3 activa-
tion was not totally dependent on Hif-1α. HIF-1α levels
were slightly increased in the RV of the MCT-2 W
group and became significantly increased in the RV of
the MCT-4 W group, but then slightly decreased in
MCT-6 W group (Fig. 7a, d). Additionally, Bcl2 peaked
in expression in the RV of the MCT-2 W group, and
then went on a gradual decline in the MCT-4 W and
MCT-6 W groups. Again, no significant differences
could be observed in autophagy signaling in controls at
these different time points (Fig. 7a, f ).
Discussion
To the best of our knowledge, this is the first study to in-
vestigate the time course of autophagy and pro-autophagy
Fig. 1 Representative pulmonary artery pressure waveforms
obtained from control and MCT-treated rats. a Waveform image
from control. b-d Waveform images from MCT-treated rats at 2
(MCT-2 W), 4 (MCT-4 W), and 6 (MCT-6 W) weeks, respectively. Black
downward arrowhead points to the dicrotic notch, and upward ar-
rows mark the diatolic recoil phase in the waveform images. Note:
PASP, pulmonary artery systolic pressure
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signalings in the RV myocardium of the MCT model. The
key findings of the present study suggest that sustained
activation of autophagy is associated with increased
pulmonary artery systolic pressure. Moreover, AMPK me-
diated mTOR as well as BNIP3-dependent Beclin-1 au-
tophagic signaling pathways were involved at distinct
stages during RV remodeling of the MCT model.
Modeling the clinical stages of progression of RV
hypertrophy to failure in the MCT rat
Studies focused on RV remodeling in PH present a
single “snapshot in time” without separating between
the stages of compensatory hypertrophy and RV fail-
ure. In addition, animal models (i.e., PAB model,
MCT model, and Sugen/hypoxia models) are used to
duplicate aspects of compensatory hypertrophy or
overt decompensated states of the RV in order to
investigate common mechanisms underlying RV re-
modeling, respectively. This may be problematic as
the cardiac hemodynamics and mechanisms of RV re-
modeling in different animal models may differ in
terms of mechanisms and severity [34, 40]. To avoid
potential confounding effects, Paulin and Sutendra
objectively measured hemodynamic criteria, clinical
features, and echocardiography of the MCT rat model
to establish the time course of the specific RV remod-
eling stages [2, 7].
Considering that autophagy may play a different role
during different phases, [20] we sought to determine the
autophagy signatures during the switch from compensa-
tory hypertrophy to failing in the RV within the MCT
model, as it progresses to PH. To reduce the variation of
rats included, the rats at each time point were also care-
fully phenotyped (e.g., with hemodynamic, clinical, and













RV/LV + IVS (g/g) 0.24 ± 0.02 0.27 ± 0.02* 0.25 ± 0.02 0.48 ± 0.06**※※ 0.23 ± 0.03 0.62 ± 0.09 **※※△
RV/BW (g/kg) 0.48 ± 0.02 0.53 ± 0.02* 0.49 ± 0.04 0.85 ± 0.06**※※ 0.45 ± 0.03 1.22 ± 0.07**※※△
BW Body weight, LW Lung weight, RV Right ventricle, LV Left ventricle, IVS Interventricular septum, MCD Myocardium cell diameter
Data are presented as mean ± standard deviation. *P < 0.05 and **P < 0.01, versus age-matched rat; ※P < 0.05, ※※P < 0.01, versus MCT-2 W; △P < 0.05,
versus MCT-4 W
Fig. 2 Representative echocardiography parameters obtained from control and MCT-treated rats at 2, 4, and 6 weeks. a-d Pulse-wave Doppler of
parasternal view at the level of the pulmonary valve leaflets, which was aligned to maximize laminar flow. White arrowhead points to midsystolic
pulmonary artery notching. Pulmonary artery acceleration time (PAAT) is highlighted by green double-headed arrows. e-h Morphology of right
ventricle presented in four-chamber view. White double-headed arrows highlights RV internal diameter during diastole. i-l Tricuspid annular plane
systolic excursion (TAPSE) highlighted by M-mode echocardiography
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echocardiography characteristics). Consistent with previ-
ous findings [2, 7], after 2 weeks of MCT treatment, the
rats experience PH and a slight increase in RV myocar-
dial hypertrophy in the absence of changes in dilatation,
which attests to the fact that the RV is likely in the early
compensatory phase. At 3–4 weeks after MCT treat-
ment, rats manifest RV enlargement, while RV function
is moderately decreased (but do not reach RV failure
cut-off values) indicative of compensatory hypertrophy
[2, 7]. At 5–6 weeks after MCT treatment, rats exhibited
typical characteristics of RV decompensation and failure
(sharp decrease in RV function parameters which reach
RV failure cut-off values for TAPSE, RV FAC, and RVEF
by echocardiography) resulting in significant mortality.
These data highlight how the MCT rat model is charac-
terized by RV failure in vivo.
Dynamic changes of autophagy in the progression RV
hypertrophy toward heart failure
A novel aspect of our data is the discovery of the time
course of autophagy-related changes from compensatory
hypertrophy to failure stages in the RV. Our results show
sustained activation of autophagy in the RV of the MCT
model—as evidenced by the presence and increased ex-
pression of the autophagy marker LC3 as well as LC3-II/
LC3-I ratio. This is consistent with Qipshidze’s finding
showing a marked increase in LC3 protein expression in
the RV of a PAB model [16]. In our work, the upregula-
tion of autophagy was further evidenced by the gradual
increase in the clustered accumulation of autophagosomal
structures in RV observed using a transmission electron
microscope. Considering the dynamic nature of autoph-
agy, the abundance of autophagosomes can reflect either
induction of autophagosome formation or a defect of
autophagosome degradation. P62 is an adaptor protein
that binds to ubiquinated protein products destined for
consumption by the autophagosome machinery. As such,
accumulation of p62 can be used as a marker of proteo-
toxicity build-up within the cell and a decrease in the
function of autophagic clearance mechanisms [14, 15].
We demonstrated the sustained upregulation of p62 dur-
ing the progression of RV remodeling, suggesting that the
autophagosome clusters may be due to an increase in
autophagy activation, rather than inhibited autophago-
some degradation. It has been shown that the MCT model
does induce a liver toxicity response; however, whether it
affects autophagy in the RV remains unclear. Interestingly,
our data revealed no obvious changes in autophagy in the
LV at different stages of the MCT model, thus highlighting
the chamber-specific nature of the autophagy induction to
the RV owing to the afterload-related changes associated
with PH, as opposed to the MCT-induced response.
Fig. 3 Histological alterations in the RV during compensatory hypertrophy and heart failure in the MCT-treated rats. a-d Cardiomyocyte
cross-sectional area and myocardial interstitial fibrosis [using wheat-germ-agglutinin staining (WGA) and Masson trichrome staining, respectively]
from control and MCT rat model. Representative images of WGA stained cardiomyocytes from control and MCT treated rats at 2, 4, and 6 weeks.
White scale represents 20 μm (×400 original magnification); (e-h) Representative images of Masson trichrome-stained RV tissues from control and
MCT treated rats at 2, 4, and 6 weeks. Red stain denotes muscle fibers. Blue stain denotes collagen. Black scale represents 50 μm (×200 original
magnification); (i) Quantitative analysis of cardiomyocyte cross-sectional (transverse) area; (j) Quantitative analysis of interstitial fibrotic area.
*P < 0.05, **P < 0.01. Values are presented as mean ± standard deviation
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Cardiac hypertrophy is an important feature of cardiac
remodeling and a recent study suggested the importance
of autophagy in the pathogenesis of cardiac hypertrophy
as it regulates cardiomyocyte protein degradation. Nakai
et al. found that knockdown of the autophagy-related
protein, autophagy-related gene 7 (Atg7), using RNAi
inhibited autophagy in rat neonatal cardiomyocytes,
which was sufficient to induce cardiomyocyte hyper-
trophy [9]. In vivo studies by the same group showed
that rapid ablation of autophagy-related gene 5 (Atg 5)
by tamoxifen treatment of an inducible cardiac-specific
Atg5-deficient mouse model resulted in an increase in
cardiomyocyte cross-sectional area [9]. More recent re-
ports have revealed that inhibition of mTOR-mediated
protein synthesis was critical for preventing pathological
hypertrophy by regulating autophagy [23, 41]. In the
present study, we showed that phosphorylation of
mTOR in the RV was significantly suppressed in the 2-
and 4- week MCT model, coinciding with an increase in
the autophagy marker LC3-II/LC3-I ratio, suggesting
that activation of autophagy at this stage may be an im-
portant target to potentially circumvent RV myocardial
hypertrophy. Additionally, we found that the upregula-
tion of LC3 levels in the RV correlated with increased
PASP. This finding supports the hypothesis that in-
creased RV pressure afterload activate oxidative
stress—caused by excess reactive oxygen species (ROS)
excess, which can play a vital role in activating autoph-
agy [16, 42]. Indeed, a previous study has shown that
ROS can inhibit autophagy-related gene 4 (Atg4), activ-
ity through oxidation of an essential cysteine residue,
which can then block the cleavage of phosphatidyletha-
nolamine (PE) from PE-conjugated LC3 and promote
autophagy [43].
Alterations and potential role of autophagy signaling
pathways
Ample evidence suggests autophagy has a principal role
in pro-survival and pro-death mechanisms dependent on
the activation of different signaling pathways [8, 44].
Thus, the potential pathways involved in autophagy
regulation were studied. It is noteworthy that both the
inhibition of AMPK/mTOR or the activation of HIF-1α/
Bcl2/ BNIP3/Beclin-1 pathways can upregulate autoph-
agy [22]. The most intriguing finding from our study is
that although persistent activation of autophagy was
observed during RV failure progression, the underlying
autophagic signaling patterns varied. AMPK is a protein
kinase activated in response to low/depleting ATP levels.
AMPK promotes cytoplasmic adenosine monophosphate
(AMP) to serve as a master negative regulator of autoph-
agy by phosphorylating and activating proteins of the tu-
berous sclerosis 1/2 complex, which then act to deactivate
phospho-mTOR and phospho-70s6K [45, 46]. We
highlight the potential reliance of autophagic activation
via AMPK-dependent inhibition of mTOR during the
compensatory phase (2 and 4 weeks after MCT treat-
ment). This observation fits with the current understand-
ing that mild ischemic stress can activate AMPK-mediated
inhibition of mTOR-dependent autophagy pathways [46].
Although it remains unclear why AMPK activity signifi-
cantly declines during end-stage heart failure, a similar
change has been noted recently in rat cardiomyocytes with
ischemic conditioning [23]. Interestingly, upregulation of
AMPK has also been observed in the LV in hypertension;
however, no inhibition of mTOR and p70s6K was ob-
served in the LV of the hypertensive rat [13]. This discrep-
ancy may be attributed to the chamber-specific stress
response to overload and differences in disease models. A
previous study on autophagy induction during ischemia
and glucose deprivation demonstrated that AMPK activa-
tion accompanied mTOR inactivation in cardiomyocytes
[46]. Inhibition of AMPK was shown to cause a significant
reduction in autophagy, while cardiomyocyte survival was
decreased by pharmacological inhibition of AMPK, sug-
gesting a protective role for AMPK-dependent autophagy
in cardiomyocytes [46]. These findings altogether suggest
a protective role for autophagy in cardiac hypertrophy
during the compensatory phase.
Another interesting finding from our study involves au-
tophagic activation via BNIP3 and Beclin-1 overexpression
during RV failure (6 weeks after MCT treatment). BNIP3 is
an important regulator of cardiomyocyte mitochondrial
function and survival during ischemic/hypoxia injury
[10, 47]. That is, the mitochondrial perturbations triggered
by BNIP3 gene activation were found to parallel opening
of the mitochondrial permeability transition pore, mito-
chondrial membrane potential loss, and cell death [48].
Although HIF-1α is an upstream molecular target of
BNIP3, [22] we showed that HIF-1α did not completely
parallel the alterations in BNIP3, suggesting that there
may be other unrecognized upstream molecular pathways
(See figure on previous page.)
Fig. 4 Expression of the autophagic marker, LC3, is upregulated in the RV of the MCT rat model. a, b RT-qPCR of LC3 mRNA expression relative
to GAPDH in RV (left) and LV (right) tissue of control and MCT-treated rats. GAPDH was used as a loading control. c, d Representative RV tissue
sections immunostained for LC3 protein (dark brown) in control and MCT-treated rats. Note: Dark brown granules in myocardial cell cytoplasm.
Black scale represents 50 μm (×200 original magnification). e, f Quantification of LC3 positive protein signal (integrated optical density) in RV (left)
and LV (right) tissue sections per field area. g Correlation of pulmonary artery systolic pressure with LC3 positive protein signal in 2, 4, and 6 week
MCT-treated rats. *P < 0.05, **P < 0.01. Values are presented as mean ± standard deviation
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involved in BNIP3 regulation in RV failure. The role of
autophagy at this stage is intriguing. A recent study dem-
onstrated that BNIP3-deficient mice exhibited diminished
cardiac dilatation and preserved ventricular systolic per-
formance post-infarction [49]. In contrast, BNIP3 overex-
pression induced progressive ventricular dilation and
impaired systolic performance possibly partly due to
increased mitochondrial apoptosis and mitophagy [50].
Consistent with this previous study, [51] we provided
evidence that BNIP3 may induce mitochondrial fragmen-
tation and autophagy. Beclin-1 is a downstream target of
BNIP3. Beclin-1 haploinsufficient mice exhibited de-
creased autophagic activity, preserved cardiac perform-
ance, and partial inhibition of cardiomyocyte death after
aortic banding [9]. Conversely, cardiac-specific Beclin-1
overexpressing mice resulted in an amplified pathological
remodeling response [52]. In addition to regulating
Beclin-1, BNIP3 may also directly act on the important
apoptosis regulator Bcl2 and trigger cell death [50].
This role may explain potential cross-talk between
autophagy and apoptosis in RV remodeling in PH.
This finding is supported the prevailing view that
maladaptive autophagy could inducing cell death [9].
The data gained from our study has provided oppor-
tunities to hypothesize a cooperative role for autophagy
and apoptosis in driving adverse pathological remodeling
of the RV by BNIP3 and Beclin-1-dependent autophagy
activation.
(See figure on previous page.)
Fig. 5 Autophagic induction in the RV of MCT rats. a, b Protein blot analysis of autophagy-related proteins, LC3II, LC3I, and p62 in RV protein
extracts from control and MCT-treated rats. β-actin was used as a loading control. c-f Quantification of LC3II to LC3-I ratio (right) and p62 (left)
protein expression normalized to β-actin levels. g Representative transmission electron micrographs from RV of control and MCT-treated rats.
Arrows indicate autophagosomes. White scale represents 2 μm (15,000× original magnification). Values are presented as mean ± standard
deviation. *P < 0.05, **P < 0.01
Fig. 6 AMPK-dependent mTOR signaling pathways are distinctly dysregulated in RV of MCT rat model. a Western blot analysis of total and
phosphorylated levels of AMPK, mTOR, and p70S6 kinase in RV protein extracts from control and MCT treated rats for 2, 4, and 6 weeks. β-actin
was used as a loading control. b-d Quantification of phosphorylated levels of AMPK, mTOR, and p70S6K to total AMPK, mTOR and p70S6K ratios.
e-g Quantification of AMPK, mTOR, and p70S6 protein band signal densities was performed using ImageJ and plotted normalized to β-actin
levels. Values are presented as mean ± standard deviation. *P < 0.05, **P < 0.01
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To date, no medications specifically target myocardial
autophagy. However, based on our new findings that
identify autophagy-associated targets, we believe that use
of mTOR inhibitors (e.g., rapamycin), AMPK activators
(e.g., AICAR), and development and use of selective
BNIP3 inhibitors in the late stages of RV compensation/
decompensation might be helpful to improve RV func-
tion and remodeling. Our findings also support previous
studies that demonstrate that treatment with rapamycin,
an inhibitor of mTOR, resulted in prevention of RV
hypertrophy and dysfunction in an animal model of PH
[53]. Thus, rapamycin may not only improve vascular
remodeling in the lung, resulting in an improvement
in RV-pulmonary artery coupling, but may also have
direct effects on autophagy regulation and thus, protection
of the RV.
Study limitations
Our study has some limitations. Firstly, we did not in-
vestigate the effects of selectively upregulating and inhi-
biting autophagy by pharmaceutical agents at different
stages of RV remodeling in PH. This was not performed
in the current study owing to the present limitation in
identifying pharmacological reagents that selectively
target cardiac autophagy. Secondly, another potential
limitation of our study is that the autophagy signatures
in the RV of the MCT model associated with PH could
be very different from other animal models of PH due to
hypoxia, Sugen/ hypoxia, hyperflow, [34] and the PAB
rat model [54]. For example, the PAB model impacts RV
hypertrophy but has no impact on the pulmonary vascu-
lature—possibly one of the important causes of RV hyp-
oxia in the MCT model that may also impact autophagy
in the RV [29]. Thus, whether our findings can apply to
other models warrants further study.
It is important to also note that it remains unclear
whether the findings in the MCT model can be general-
ized to humans. Thus, future studies should also
consider the assessment of autophagy signatures in RV
tissues, of PH patients with different etiologies. Further-
more, fibrosis is an important feature of RV remodeling;
however, our study does not assess a causality chain be-
tween myocardial fibrosis and these autophagic signaling
pathways. Thus, comprehensive in vivo and in vitro
studies are required to test this hypothesis in the future.
Conclusions
Our findings highlight that persistent up-regulated autoph-
agy was associated with increased pressure overload. Most
importantly, different signaling mechanisms (mTOR
and Beclin-1 mediated pathways) are involved in au-
tophagy activation of the RV in the MCT rat model.
These findings may have broad implications in better
designing pharmacological strategies to protect against
RV remodeling and dysfunction in PH in a stage-
specific manner.
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